tert-butyl 3-(3-formylphenyl)acrylate | 934622-50-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: tert-butyl 3-(3-formylphenyl)acrylate
• 英文别名: tert-butyl (E)-3-(3-formylphenyl)acrylate；(E)-tert-butyl 3-(3-formylphenyl)acrylate；tert-butyl (E)-3-(3-formyl-phenyl)-acrylate；tert-butyl (E)-3-(3-formylphenyl)prop-2-enoate
• CAS: 934622-50-1
• 化学式: C₁₄H₁₆O₃
• 分子量: 232.279
• InChiKey: VDZPCCSFNFMEHY-BQYQJAHWSA-N

物化性质

• 沸点：
  354.0±25.0 °C(Predicted)
• 密度：
  1.097±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-(3-formylphenyl)acrylate 在 sodium tetrahydroborate 、 水 作用下， 以 乙醇 为溶剂， 反应 1.5h， 以86%的产率得到tert-Butyl(2E)-3-[3-(hydroxymethyl)phenyl]-2-propenoate
  参考文献：
  名称：

  Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure

  摘要：

  Small molecules that act on multiple biological targets have been proposed to combat the drug resistance commonly observed for cancer chemotherapy. By combining the structural features of known inhibitors of inosine monophosphate dehydrogense (IMPDH) and histone deacetylase (HDAC), dual inhibitors of IMPDH and HDAC based on the scaffold of cinnamic hydroxamic acid (CHA) have been designed, synthesized, and evaluated in biological assays. Key features, including the linker length, linker functionality, substitution position, and interacting groups, have been explored. Their individual contribution to the inhibitory activities against human IMPDH1 and IMPDH2 as well as HDAC has been assessed. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.081
• 作为产物：
  描述：

  间溴苯甲醛 、 丙烯酸叔丁酯 在 palladium diacetate 、 三苯基膦 碳酸氢钠 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 以56%的产率得到tert-butyl 3-(3-formylphenyl)acrylate
  参考文献：
  名称：

  A new class of histone deacetylase inhibitors

  摘要：

  这项发明涉及新的组蛋白去乙酰化酶抑制剂，其通式为（I），其中：Q是键，CH2，NR5或氧，X是CH或氮，Y是键，CH2，氧或NR6，Z是CH或氮，R1，R2分别是氢或C1-C6烷基，R3，R4分别是氢，卤素，C1-C6烷基，C1-C6烷氧基，C1-C6卤代烷基或C1-C6卤代烷氧基，R5和R6的进一步定义在说明书中，并且其药用盐是可以接受的。

  公开号：

  EP2033956A1

文献信息

• Synthesis and Spectral Characterization of Related Substances of Lacidipine, an Antihypertensive Drug
  作者：V. V. N. K. V. Prasada Raju、Ganta Madhusudhan Reddy、Vedantham Ravindra、Vijayavitthal T. Mathad、P. K. Dubey、Padi Pratap Reddy

  DOI：10.1080/00397910802638560

  日期：2009.5.22

  Abstract Five related substances (impurities) were detected in lacidipine bulk drug substance by a simple high-performance liquid chromatographic method (HPLC) and were identified by liquid chromatography–mass spectrometry (LC-MS). These related substances were independently synthesized, characterized, and co-injected with the sample containing impurities.

  摘要 采用简单的高效液相色谱法 (HPLC) 检测拉西地平原料药中的 5 种相关物质（杂质），并通过液相色谱-质谱法 (LC-MS) 进行鉴定。这些相关物质是独立合成、表征的，并与含有杂质的样品共同进样。
• Bench-Stable and Recoverable Palladium(I) Dimer as an Efficient Catalyst for Heck Cross-Coupling
  作者：Franziska Schoenebeck、Theresa Sperger、Christopher Stirner

  DOI：10.1055/s-0036-1588318

  日期：——

  elevated-temperature conditions, allowing its recovery after reaction completion and recycling. The application of air- and moisture-stable dinuclear palladium(I) complex [Pd(μ-I)(Pt-Bu3)]2 as an efficient catalyst for the Heck cross-coupling reaction of aryl iodides and bromides with acrylates and styrenes is described. The developed protocol is robust and operationally simple and shows a high functional-group

  摘要 空气和水分稳定的双核钯（I）配合物[Pd（μ-I）（P t -Bu 3）] 2作为芳基碘化物和溴化物与丙烯酸酯和丙烯酸的Heck交叉偶联反应的有效催化剂的应用。描述了苯乙烯。所开发的协议功能强大且操作简单，并且具有很高的功能组容限。所使用的钯（I）二聚体催化剂在这些亲核以及高温条件下具有很高的耐用性，可以在反应完成并循环使用后回收。 空气和水分稳定的双核钯（I）配合物[Pd（μ-I）（P t -Bu 3）] 2作为芳基碘化物和溴化物与丙烯酸酯和丙烯酸的Heck交叉偶联反应的有效催化剂的应用。描述了苯乙烯。所开发的协议功能强大且操作简单，并且具有很高的功能组容限。所使用的钯（I）二聚体催化剂在这些亲核以及高温条件下具有很高的耐用性，可以在反应完成并循环使用后回收。
• Substituted phenyl compounds
  申请人：Rhone-Poulenc Rorer Limited

  公开号：US06211234B1

  公开（公告）日：2001-04-03

  Compounds of formula (I) are described wherein R1 is hydrogen, -(lower alkyl)q(CO2R6 or OH), —CN, —C(R7)═NOR8, NO2, —O(lower alkyl)R9, —C≡C—R10, —CR11═C(R12)(R13), —C(═O)CH2C(═O)CO2H, —CO(R14), alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, thiocarbamoyl, substituted carbamoyl, substituted thiocarbamoyl, sulphamoyl or an optionally substituted nitrogen-containing ring, m, n, o and p are independently zero or 1 and R2, R3, R4 and R5 are various groups; and physiologically acceptable salts, N-oxides and prodrugs thereof. The compounds have endothelin antagonist activity and are useful as pharmaceuticals.

  式(I)的化合物描述如下，其中R1为氢，-(较低烷基)q(CO2R6或OH)，—CN，—C(R7)HNOR8，NO2，—O(较低烷基)R9，—C≡C—R10，—CR11CH(R12)(R13)，—C(O)CH2C(O)CO2H，—CO(R14)，烷基硫醚，烷基亚砜基，烷基磺酰基，氨基甲酰基，硫代氨基甲酰基，取代的氨基甲酰基，取代的硫代氨基甲酰基，磺酰胺基或可选择取代的含氮环，m、n、o和p独立地为零或1，R2、R3、R4和R5为各种基团；以及其生理学上可接受的盐、N-氧化物和前药。这些化合物具有内皮素拮抗活性，并可用作药物。
• NEW CLASS OF HISTONE DEACETYLASE INHIBITORS
  申请人：Minucci Saverio

  公开号：US20120115867A1

  公开（公告）日：2012-05-10

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH 2 , NR 5 or oxygen, X is CH or nitrogen, Y is a bond, CH 2 , oxygen or NR 6 , Z is CH or nitrogen, R 1 , R 2 are, independently, hydrogen or C 1 -C 6 alkyl, R 3 , R 4 are, independently, hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl or C 1 -C 6 haloalkoxy, and R 5 and R 6 are as further defined in the specification, and pharmaceutical acceptable salts thereof.

  本发明涉及一种新的组蛋白去乙酰化酶抑制剂，其通式为(I)，其中：Q是键，CH2，NR5或氧，X是CH或氮，Y是键， ，氧或NR6，Z是CH或氮，R1、R2是独立的氢或C1-C6烷基，R3、R4是独立的氢、卤素、C1-C6烷基、C1-C6烷氧基、C1-C6卤代烷基或C1-C6卤代烷氧基，R5和R6的定义在说明书中进一步给出，以及其药物可接受的盐。
• CLASS OF HISTONE DEACETYLASE INHIBITORS
  申请人：Thaler Florian

  公开号：US20100305123A1

  公开（公告）日：2010-12-02

  This invention is related to new histone deacetylase inhibitors according to the general formula (I) wherein: Q is a bond, CH 2 , NR 5 or oxygen, X is CH or nitrogen, Y is a bond, CH 2 , oxygen or NR 6 , Z is CH or nitrogen, R 1 , R 2 are, independently, hydrogen or C 1 -C 6 alkyl, R 3 , R 4 are, independently, hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl or C 1 -C 6 haloalkoxy, and R 5 and R 6 are as further defined in the specification, and pharmaceutical acceptable salts thereof.

  本发明涉及一种新的组蛋白去乙酰化酶抑制剂，其通式为（I），其中：Q是键，CH2，NR5或氧，X是CH或氮，Y是键， ，氧或NR6，Z是CH或氮，R1，R2独立地是氢或C1-C6烷基，R3，R4独立地是氢，卤素，C1-C6烷基，C1-C6烷氧基，C1-C6卤代烷基或C1-C6卤代烷氧基，R5和R6的进一步定义在规范中，并且包括其药学上可接受的盐。